MAPK/ERK Pathway

Overview

The mitogen-activated protein kinase (MAPK) / extracellular signal-regulated kinase (ERK) pathway is one of the most extensively studied signal transduction cascades in cell biology. It converts extracellular stimuli — particularly growth factors, cytokines, and mitogens — into intracellular responses that drive cell proliferation, differentiation, survival, and migration. The pathway operates through a conserved three-tier kinase relay: MAPKKK (MAP kinase kinase kinase) activates MAPKK (MAP kinase kinase), which activates MAPK (MAP kinase).

In mammals, four major MAPK cascades exist: ERK1/2, JNK (c-Jun N-terminal kinase), p38 MAPK, and ERK5. The Ras-Raf-MEK-ERK1/2 cascade is the canonical and best-characterized branch, serving as the primary mitogenic signaling pathway downstream of receptor tyrosine kinases (RTKs) and G-protein coupled receptors. In peptide research, the MAPK/ERK pathway is relevant as a downstream effector of numerous peptide ligand-receptor interactions and as a mediator of tissue repair and angiogenic signaling.

How It Works

Receptor Activation and Ras Engagement

Receptor tyrosine kinase activation

• Growth factors (EGF, FGF, PDGF, VEGF, IGF-1) bind their cognate RTKs, inducing receptor dimerization and trans-autophosphorylation of cytoplasmic tyrosine residues
• Phosphotyrosine residues serve as docking sites for SH2 domain-containing adaptor proteins

Ras activation cycle

• The adaptor protein GRB2 (growth factor receptor-bound protein 2) binds phosphorylated RTKs via its SH2 domain
• GRB2 constitutively binds the guanine nucleotide exchange factor (GEF) SOS (Son of Sevenless) via its SH3 domains
• Membrane-recruited SOS catalyzes GDP-to-GTP exchange on Ras, activating it
• Active Ras-GTP has a conformational change in its effector-binding domain (switch I and II regions)
• Ras is inactivated by GTPase-activating proteins (GAPs), particularly NF1 (neurofibromin), which accelerate GTP hydrolysis

The Three-Tier Kinase Cascade

Tier 1: MAPKKK (Raf kinases)

• Active Ras-GTP recruits Raf kinases (A-Raf, B-Raf, or C-Raf/Raf-1) to the plasma membrane
• Membrane recruitment enables Raf dimerization and activation through a complex series of phosphorylation events
• B-Raf has the highest basal kinase activity and is the predominant MAPKKK in many cell types
• C-Raf activation requires additional inputs including phosphorylation by Src family kinases and release from 14-3-3 inhibitory binding

Tier 2: MAPKK (MEK1/2)

• Active Raf phosphorylates MEK1 and MEK2 (MAP/ERK kinases) on two serine residues (Ser218 and Ser222 in MEK1)
• MEK1/2 are dual-specificity kinases — they phosphorylate both threonine and tyrosine residues on their substrates
• MEK1/2 are the only known physiological activators of ERK1/2, creating a highly specific bottleneck in the pathway

Tier 3: MAPK (ERK1/2)

• MEK1/2 phosphorylate ERK1 (p44 MAPK) and ERK2 (p42 MAPK) on the Thr-Glu-Tyr (TEY) motif in the activation loop
• Dual phosphorylation on both Thr202 and Tyr204 (ERK1 numbering) is required for full activation
• Active ERK1/2 dimerize and translocate to the nucleus, although they also phosphorylate cytoplasmic substrates

Downstream Targets and Outputs

Nuclear targets

• ERK1/2 phosphorylate transcription factors including Elk-1, c-Fos, c-Myc, and Ets family members
• Phospho-Elk-1 activates the serum response element (SRE), driving immediate early gene expression (c-Fos, Egr-1)
• ERK phosphorylates and stabilizes c-Myc and c-Fos, promoting cell cycle entry

Cytoplasmic targets

• RSK (p90 ribosomal S6 kinase) — phosphorylated by ERK; activates CREB, promotes translation, and contributes to mTOR activation
• MNK1/2 — phosphorylate eIF4E, enhancing cap-dependent mRNA translation
• Cytoskeletal regulators — ERK phosphorylates paxillin, FAK, and calpain, modulating cell migration

Negative feedback loops

• ERK phosphorylates SOS, disrupting the GRB2-SOS interaction and reducing Ras activation
• ERK phosphorylates Raf, creating 14-3-3 binding sites that inhibit Raf activity
• ERK induces expression of DUSP (dual-specificity phosphatase) family members, which dephosphorylate and inactivate ERK
• Sprouty proteins are induced by ERK and inhibit Ras or Raf activation

Parallel MAPK Cascades

JNK pathway (stress-activated)

• Activated by cellular stress, UV radiation, cytokines (TNF-alpha, IL-1)
• Cascade: MLK/ASK1 → MKK4/MKK7 → JNK1/2/3
• Phosphorylates c-Jun, ATF2; regulates apoptosis and inflammation

p38 MAPK pathway (stress/inflammation)

• Activated by inflammatory cytokines, osmotic stress, UV radiation
• Cascade: MLK/ASK1/TAK1 → MKK3/MKK6 → p38alpha/beta/gamma/delta
• Regulates cytokine production, apoptosis, and cell cycle arrest

Key Components

Role in Peptide Research

Growth Factor-Mimetic Peptides

Peptides that stimulate the growth hormone axis — including GHRP-6, ipamorelin, and CJC-1295 — activate the MAPK/ERK pathway through the GH receptor (a JAK2-coupled receptor) and indirectly through IGF-1-mediated RTK signaling. The proliferative and differentiation effects of GH-releasing peptides are partially mediated through ERK-dependent transcriptional programs.

BPC-157

BPC-157 has been shown to activate ERK1/2 signaling in multiple tissue types, including tendon fibroblasts, endothelial cells, and intestinal epithelial cells. ERK activation by BPC-157 contributes to its documented effects on cell migration, proliferation, and VEGF signaling-mediated angiogenesis.

VEGF-Related Peptides

Vascular endothelial growth factor signals through VEGFR2, which activates ERK1/2 via the PLCgamma-PKC-Raf-MEK axis. Peptides that modulate angiogenesis — including those that promote or inhibit VEGF signaling — exert their vascular effects partly through MAPK/ERK-dependent endothelial cell proliferation and migration.

Melanocortin Peptides

The melanocortin system signals through melanocortin receptors (MC1R-MC5R), which are GPCRs that can activate ERK1/2 via PKA-dependent and beta-arrestin-dependent mechanisms. Alpha-MSH and its analogs (melanotan II, PT-141) engage MAPK/ERK signaling in melanocytes and other target cells.

Clinical Significance

• Cancer — Oncogenic mutations in the MAPK/ERK pathway are among the most common in human cancer. KRAS mutations occur in approximately 25% of all cancers (90% of pancreatic, 45% of colorectal). BRAF V600E mutations drive melanoma (50%), thyroid cancer, and colorectal cancer. Targeted therapies include Raf inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (trametinib, cobimetinib).
• RASopathies — Germline mutations in Ras-MAPK pathway components cause a group of developmental disorders including Noonan syndrome (SHP2/PTPN11), Costello syndrome (H-RAS), and neurofibromatosis type 1 (NF1).
• Wound healing — ERK signaling is essential for the proliferative phase of wound repair, driving fibroblast proliferation, keratinocyte migration, and angiogenesis. See wound healing protocol. Impaired ERK activation contributes to chronic non-healing wounds.
• Cardiac hypertrophy — Sustained ERK activation contributes to pathological cardiac hypertrophy, while intermittent ERK activation appears cardioprotective.
• Neurodegenerative disease — ERK signaling supports neuronal survival and synaptic plasticity. Impaired MAPK/ERK signaling in neurons is associated with Alzheimer's disease and Parkinson's disease pathology.

Related Topics

• mTOR Pathway — ERK activates mTORC1 via RSK-mediated TSC2 phosphorylation
• NF-kB Pathway — Cross-talk in inflammatory and proliferative signaling
• TGF-Beta Signaling — TGF-beta activates ERK through non-canonical mechanisms
• VEGF Signaling — ERK mediates VEGFR2-driven endothelial proliferation
• GPCR Signaling — GPCRs activate ERK via multiple mechanisms